Table 2.
Routine and experimental laboratory parameters of prostate cancer patients with DIC, age- and stage-matched prostate cancer patients without DIC, and age-matched healthy individuals.
| Laboratory Parameter (Median, Range) | Prostate Cancer Patients with DIC (n = 7) | Prostate Cancer Patients without DIC (n = 10) | Healthy Controls (n = 10) | p-Value Patients with DIC Versus Patients without DIC | p-Value Patients with DIC Versus Healthy Controls | p-Value Patients without DIC Versus Healthy Controls |
|---|---|---|---|---|---|---|
| Routine parameter: Thrombocyte count, ×103/μL |
36 (24 to 119) | 244.50 (177 to 528) | 213.50 (172 to 326) | 0.001 | 0.001 | 0.273 |
| Leukocyte count, ×109/L | 5.69 (2.56 to 26.59) | 7.36 (4.22 to 9.59) | 5.95 (4.45 to 8.71) | 0.040 | 0.354 | 0.131 |
| Fibrinogen, % | 99 (55 to 178) | 379 (299 to 662) | 331 (245 to 402) | 0.001 | 0.001 | 0.130 |
| Prothrombin time, % | 60 (50 to 70) | 105 (86 to 124) | 98 (94 to 104) | 0.012 | 0.001 | 0.462 |
| aPTT, s | 47.9 (40.0 to 65.20) | 34.7 (24.5 to 40.6) | 34.35 (29.70 to 36.6) | 0.001 | 0.001 | 0.940 |
| D-Dimer, ng/mL | 44.83 (10.65 to 314.29) | 0.53 (0.20 to 2.55) | 0.39 (0.27 to 0.69) | 0.001 | 0.001 | 0.362 |
| PSA, ng/mL | 264.7 (110.0 to 5000) | 15 (0.5 to 680) | 1.90 (0.97 to 2.81) | 0.008 | 0.016 | 0.043 |
| CRP, ng/mL | 5.53 (1.17 to 53.20) | 0.54 (0.07 to 4.20) | 0.19 (0.03 to 0.53) | 0.007 | 0.001 | 0.050 |
| Experimental parameters: | ||||||
| EV-TF activity, pg/mL | 11.40 (4.34 to 27.06) | 0.09 (0.00 to 0.30) | 0.18 (0.09 to 0.54) | 0.001 | 0.001 | 0.096 |
| Fibrin clot formation time, s | 346 (244.3 to 775) | 948 (704 to 1312) | 900 (583 to 1067) | 0.001 | 0.001 | 0.496 |
| Fibrin clot formation time + anti-TF antibody, s | 920 s (725.5 to 1177) | 975.5 (393 to 1640) | 809 (591 to 1187) | 0.669 | 0.161 | 0.104 |
>Bold p-values indicate statistical significance after Bonferroni correction (p < 0.01667). EV-TF—extracellular-vesicle-associated tissue factor.